Yorktown Management & Research Co Inc raised its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 294.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,700 shares of the medical research company’s stock after buying an additional 5,000 shares during the period. Yorktown Management & Research Co Inc’s holdings in Amgen were worth $1,237,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Kwmg LLC purchased a new stake in shares of Amgen during the second quarter worth about $108,000. Braun Bostich & Associates Inc. purchased a new stake in shares of Amgen during the first quarter worth about $113,000. WealthTrust Fairport LLC purchased a new stake in shares of Amgen during the first quarter worth about $121,000. Cornerstone Advisors Inc. boosted its holdings in shares of Amgen by 76.5% during the first quarter. Cornerstone Advisors Inc. now owns 729 shares of the medical research company’s stock worth $124,000 after purchasing an additional 316 shares during the period. Finally, Gables Capital Management Inc. purchased a new stake in shares of Amgen during the first quarter worth about $174,000. Institutional investors and hedge funds own 77.20% of the company’s stock.
Several analysts have commented on the stock. TheStreet upgraded shares of Amgen from a “c+” rating to a “b-” rating in a report on Friday, May 25th. Wells Fargo & Co restated a “neutral” rating and issued a $197.00 price objective on shares of Amgen in a report on Wednesday, August 29th. JPMorgan Chase & Co. raised their price objective on shares of Amgen from $191.00 to $192.00 and gave the stock a “neutral” rating in a report on Friday, July 27th. BidaskClub upgraded shares of Amgen from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 11th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $200.00 price objective on shares of Amgen in a report on Monday, July 16th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $202.76.
Shares of NASDAQ AMGN opened at $196.73 on Wednesday. Amgen, Inc. has a fifty-two week low of $163.31 and a fifty-two week high of $201.23. The company has a market cap of $129.33 billion, a price-to-earnings ratio of 15.64, a price-to-earnings-growth ratio of 1.95 and a beta of 1.40. The company has a quick ratio of 3.12, a current ratio of 3.39 and a debt-to-equity ratio of 2.03.
Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.52 by $0.31. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $5.73 billion. During the same quarter last year, the firm earned $3.27 earnings per share. The business’s revenue for the quarter was up 4.3% on a year-over-year basis. sell-side analysts anticipate that Amgen, Inc. will post 13.95 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 7th. Shareholders of record on Friday, August 17th will be paid a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.68%. The ex-dividend date of this dividend is Thursday, August 16th. Amgen’s dividend payout ratio is 41.97%.
In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $184.27, for a total transaction of $281,011.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.27% of the stock is currently owned by company insiders.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Featured Story: Trading Strategy Examples and Plans
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.